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INTRODUCTION 
 
 
A. Metabolic bone disease 
 
 
Bone metabolism: 
 
 
Remodelling of bone continues throughout life in response to  
mechanical  stimuli  and other regulatory factors. The normal sequence of 
bone remodeling involves 4  steps, the first of which is activation of  
osteoclasts by osteoblasts . The next step is bone resorption, which  
involves replication of osteoclast precursors and their differentiation,  
migration and fusion into mature osteoclasts. The third phase begins 
when the osteoclasts have resorbed most of the mineral and  
matrix. This is the reversal step or coupling, meaning the reversal from 
bone  resorption to formation, the signal for which is not definitely 
known . The last step is the formation of new bone by osteoblasts filling 
the resorption cavity. Mineralization then follows within a few days. This 
sequence of activation, resorption, reversal, formation and  
mineralization occurs normally on 10 percent of the bone surface and has 
a duration of several months. The remodelling process is regulated by  
circulating hormones and by local factors (Figure 1). 
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Figure 1.Normal bone remodeling (Ljunghall et al, Doctors Manual, 1995) 
 
 
Hormones that influence the rate of normal bone remodeling are 
most notably parathyroid hormone (PTH), vitamin D and calcitonin.  
Increased PTH levels stimulate bone remodelling by increasing resorp-
tion. Vitamin D, as its active  metabolite 1,25-dihydroxy vitamin D3 
(1,25(OH)2 D3) (the 25 hydroxylation step taking place in the liver), is 
essential for mineralization of new bone and is also a potent bone  
resorption agent. The full role of vitamin D in normal bone  metabolism 
is not clearly understood. Other important hormones in bone  
metabolism are growth hormone (GH), thyroid hormone and sex steroids.  
Examples of other systemic and local factors affecting osteoblast and/or 
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osteoclast function are interleukin-1 and -6, transforming growth  
factor-B(TGF-B) and  insulin-like growth factors (IGF). There are two 
types of  bone tissue in adult life, trabecular and cortical bone. Trabecular 
bone is concentrated in the spine and at the ends of long bones and  
constitutes about 25% of the total bone mass. The annual turnover rate in 
trabecular bone is about 25% and in cortical bone about  
2-3% making trabecular bone more vulnerable to factors influencing  
bone metabolism . Bone mass is determined by the peak bone mass 
achieved around the age of 20-30 and the subsequent gradual loss of  
bone by about 0.5-1% per year. Bone mass is higher in men than in wom-
en throughout adult life, and in women there is an accelerated bone in 
loss in the first years after menopause at about 2% per year . During the 
course of their lifetime, women lose about 50% and men 30% of their 
trabecular bone. 
 
Osteoporosis and osteomalacia: 
 
 Osteoporosis and osteomalacia are two forms of metabolic bone 
disease. Osteoporosis is defined as a systemic disease of the skeleton, 
characterized by low  bone mass and altered micro-architecture of bone 
tissue, with a consequent   increase in bone fragility and susceptibility to 
fracture . There is a disintegration of  the bone matrix with normal ratio 
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of mineral to matrix . Primary osteoporosis includes postmenopausal  
osteoporosis (type I osteoporosis) and senile osteoporosis (type II  
osteoporosis) of elderly women and men. Postmenopausal osteoporosis is 
characterized by increased bone resorption (high bone turnover) due to 
estrogen deficiency. There is predominantly a loss of trabecular bone 
with resulting fractures mainly at the vertebrae. 
 
 In senile osteoporosis the loss of trabecular and cortical bone is 
similar due to the combined effects of increased resorption and decreased 
bone formation (low bone turnover) and is associated with vertebral or 
hip fractures. Other general risk factors for osteoporosis are low body 
weight, physical inactivity, smoking, and genetic factors. Secondary  
osteoporosis refers to bone loss caused by a specific defined clinical  
disorder. Secondary osteoporosis can be either high or low bone turnover 
osteoporosis depending on the cause. 
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Table 1. Causes of secondary osteoporosis in adults 
 
 
 
 
Endocrine/metabolic 
 
Hypogonadism 
 
Hyperadrenocorticism 
 
Thyrotoxicosis 
 
Systemic mastocytosis 
 
 
 
 
 
 
Nutritional 
 
Malabsorption/malnutrition 
 
Chronic liver disease 
 
Vitamin D deficiency 
 
Anorexia nervosa 
 
Alcoholism 
 
Gastric surgery 
 
 
 
 
 
Drugs 
 
Glucocorticosteroids 
 
Chronic heparin administration 
 
Anticonvulsants 
 
 
 
 
 
 
 
 
Other 
 
Osteogenesis imperfecta 
 
Ehler-Danlos syndrome 
 
Marfan syndrome 
 
Myeloma 
 
Immobilization/space flight 
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Osteomalacia is rare in developed countries but is characterized by  
impaired mineralization of bone matrix, most often due to vitamin D  
deficiency. Biochemical abnormalities are common in osteomalacia but 
the diagnosis is best established by use of transiliac bone biopsy in  
combination with the use of timed tetracycline. The histological  
examination of the undecalcified bone shows an increase in the amount of 
unmineralised osteoid and depressed rate of bone formation. 
 
Measurements of bone mineral density: 
 
 
Bone mineral density (BMD;g/cm2) is measured by non-invasive 
methods based  on radiology. A specified amount of electromagnetic en-
ergy, in the form of a Gamma or X-ray beam, is sent through a region of 
interest and the amount exiting is quantified by a detector. Single  
photon  absorptiometry (SPA), introduced in the 1960s measures BMD 
reliably only at peripheral sites, having small amounts of  surrounding  
tissue, such as the heel and the wrist. Dual-energy X-ray  absorptiometry 
(DEXA) was introduced in the late 80-ies and is now the most  
widespread technique for evaluating BMD in patients at risk of  
osteoporosis. With  DEXA, two distinct energy levels are used to resolve 
contributions from soft tissue and bone making it possible to measure 
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BMD at central sites such as the  spine and the proximal femur. The  
precision error for DXA is about 1-2% which is important when  
estimating bone loss in longitudinal studies. If expected bone loss is of 
the same order, i.e. 1-2% per year, measurements should be performed 
with not less than1-2 year’s interval. Since 1994 the World Health 
 Organization (WHO) has recognized a working definition where  
osteoporosis is defined as a BMD value of 2.5 SDs below the mean for 
healthy young  women (Table 2). No such generally accepted definition 
of osteoporosis exists for men at the present. 
 
 
Table 2.World Health Organization (WHO) working defini-
tion. 
 
 
Bone mineral density Classification 
 
Above –1 SDNormal 
 
Between –1 SD and –2.5 SD Low bone mass or osteopenia 
 
Below –2.5 SD Osteoporosis 
 
Below –2.5 SD and fractures Severe osteoporosis 
 
The comparison with the mean BMD for young adults of the same 
sex is termed the Tscore and is expressed as the number of standard  
deviations from the reference group mean value. Thus, according to the 
WHO´s definition, a woman with a T-score below–2.5 has osteoporosis. 
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In clinical practice the use of T- scores has also been adopted for men. A 
Z-score is the number of standard deviations from age-matched and 
weight adjusted reference population of the same sex. 
B. Metabolic bone disease in chronic liver disease 
 
Chronic liver disease: 
 
Chronic liver disease (CLD) can be classified into diseases with 
primarily hepato-cellular damage and cholestatic diseases. Examples of 
hepato-cellular CLD are autoimmune chronic hepatitis (AICAH), chronic 
viral hepatitis B and C and alcoholic  liver disease. Autoimmune CAH is 
a disease of unknown etiology, has a  prevalence of about 5-10/100.000. 
It occurs mainly in young women (sex ratio 8:1) and is treated with  
longterm corticosteroid therapy. Alcoholic liver disease includes  
steatosis, which is reversible upon abstinence, alcoholic hepatitis and  cir-
rhosis. Alcohol is the most common cause of liver cirrhosis in India. 
 
Liver failure and the Child-Pugh classification: 
 
 
The final stage of chronic inflammation in the liver is cirrhosis. 
Liver cirrhosis  gives rise to portal  hypertension and complications such 
as bleeding due to esophageal varices, ascites and encephalopathy.  
Hepato-cellular failure results in  hyperbilirubinemia, hypoalbuminemia 
and prolonged prothrombin time. Child´s grade is  used to assess  
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hepatocellular function in cirrhosis based on these factors. The Child-
Pugh classification is a modified grading system shown to be reliable in 
predicting survival of patients presenting with variceal bleeding but is  
also widely used as a method of assessing liver function  (Table 3). 
 
Table 3. Child-Pugh classification of hepatic functional reserve in  
cirrhosis 
 
 
ASSESSMENT 
CRITERA 
 
POINTS SCORED 
1 2 3 
ENCEPHALOPATHY NONE 
 
1-2 3-4 
ASCITES NONE SLIGHT MOD 
BILIRUBIN(mg/dl) <2 2-3 >3 
ALBUMIN(g/dl) >3.5 2.8-3.5 <2.8 
PROTHROMBIN 
TIME(INR) 
<1.7 1.7-2.2 >2.2 
 
CLASS A: 5-7; CLASS B: 8-9; CLASS C: 10-15 
 
 
Hepatic Osteodystrophy: 
 
 
 
In 1939 a 69 year old woman with long-standing intrahepatic  
obstructive jaundice and spinal osteoporosis with vertebral compressions 
was described . Since then it has been firmly established that chronic cho-
lestasis, and also other forms of CLD, are associated with metabolic bone 
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disease. In the era of liver transplantation, metabolic bone disease com-
plicating CLD has become a major clinical problem. After liver trans-
plantation the combination of  high dose corticosteroids and  
immobilization accelerates bone loss leading to a high post-transplant 
fracture rate ranging from 17-65%. Decreased BMD pre-transplant,  
however, is a major risk factor for the development of post-transplant 
fracture .The term ―hepatic osteodystrophy‖ covers both osteomalacia 
and osteoporosis.Steathorrhea with malabsorption of fat-soluble vitamins, 
including vitamin D, accompanies  symptomatic cholestatic liver disease. 
Therefore osteomalacia might be expected to complicate CLD, as in fact 
was reported in earlier studies [36-37].  
 
But over the last two decades, better histomorphometric techniques  
(including  double-Tetracycline labeling for diagnosing osteomalacia) 
have made it clear that the main bone abnormality in CLD, cholestatic or 
hepato-cellular, is osteoporosis  and that osteomalacia is very rare. Most 
histomorphometric studies have found osteoporosis in CLD to be of a low 
bone turnover type with reduced osteoblast function, and measurements 
of  biochemical markers of bone metabolism, such as osteocalcin, have 
confirmed  these findings . 
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The pathogenesis of osteoporosis in CLD is unknown. Advanced 
liver disease  and cirrhosis are associated with an increased prevalence of 
osteoporosis . The way in which liver failure affects osteoblasts and  
contributes to the development of osteoporosis is unclear. Numerous 
growth factors, some of which  affect  osteoblast  function, such as IGF-l 
and TGF-β, are synthesized by the liver.  
 
Toxic substances, such as aluminium and copper, which  
accumulate in liver failure might also affect bone metabolism. In  
haemochromatosis an increased iron burden might impair osteoblastic  
activity .  Bilirubin has been shown to inhibit osteoblast proliferation in 
vitro . Whether cholestasis per se is a risk factor for osteoporosis in  CLD 
is uncertain. Cholestatic CLD has traditionally been considered to be   
associated with osteoporosis more than other types of CLD and most  
studies of metabolic bone disease in CLD involve women with PBC. In 
pre-transplant patients suffering from different liver disorders, the  
highest prevalence of  metabolic bone disease was found in patients with 
PBC and PSC. Other studies, however, have reported similar prevalence 
rates for osteoporosis in patients with hepato-cellular CLD as in patients 
with cholestatic CLD, ranging from 9 to 53% . Low levels of serum  
vitamin D3 metabolites and calcium malabsorption are found in CLD . 
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Whether vitamin D deficiency is associated with metabolic bone disease 
in CLD is uncertain.   
 
1 ,25-dihydroxyvitamin D [1,25(OH)2D] is the major steroid  
hormone involved in mineral ion homeostasis regulation. In  
response to ultraviolet radiation of the skin, a photochemical cleavage  
results in the formation of vitamin D from 7-dehydrocholesterol. Vitamin 
D from plant sources is in the form of vitamin D2, whereas that from  
animal sources is vitamin D3. Vitamin D enters the circulation, whether 
absorbed from the intestine or synthesized cutaneously, bound to vitamin 
D–binding protein, an  alpha-globulin synthesized in the liver. Vitamin D 
is subsequently 25-hydroxylated in the liver by cytochrome P450–like 
enzymes in the mitochondria and microsomes. The second hydroxylation, 
required for the formation of the mature hormone, occurs in the kidney. 
Since one of the essential steps of Vitamin D3 formation occurs in the 
liver this process may be affected in chronic liver disease. Further there 
may be impaired absorption and reduced enterohepatic circulation in  
patients with chronic liver disease. Vitamin D insufficiency leads to  
compensatory hyperparathyroidism and this is an important risk factor for 
osteoporosis and fractures. Vitamin D inadequacy may also affect risk 
and/or severity of other diseases including cancers  
(colorectal/prostate/breast), autoimmune diseases and diabetes. 
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So Vitamin D may play an important role in causing metabolic bone  
disease in chronic liver disease patients. The aim of this study is to find 
out the 25(OH) vitamin D3 and parathyroid hormone disturbances that 
occur in chronic liver disease patients so that their role in causing bone 
disease can be established. It may open up other treatment options like 
vitamin D supplementation. Further their levels are correlated with the 
severity of liver disease calculated as per Child Pugh scoring system.  
 
Hyperparathyroidism, despite vitamin D replacement, has been described 
in PBC .Others have not found evidence of hyperparathyroidism in  
patients with CLD .Treatment with corticosteroids and hypogonadism in 
men and women are reported by some as risk factors for osteoporosis in 
CLD. Others have not found treatment with corticosteroids to be  
associated with low BMD in CLD.  Other general factors in patients with 
CLD such as alcohol consumption, low body weight and physical  
inactivity have not been reported as independent risk factors for  
osteoporosis in CLD but can be assumed to be important. 
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Potential pathophysiological factors in osteoporosis in 
chronic liver disease 
 
 
 
 
Lack of growth factors produced by the liver 
 
Accumulation of toxins 
 
Cholestasis 
 
Hyperbilirubinemia 
 
Vitamin D deficiency 
 
Vitamin K deficiency 
 
Calcium deficiency 
 
Hypogonadism 
 
Treatment with corticosteroids 
 
Alcohol consumption 
 
Low body weight 
 
Physical inactivity 
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AIMS AND OBJECTIVES 
 
 
 
1.To determine the prevalence of osteoporosis in patients with 
Decompensated chronic liver disease ,  
 
 
2. To analyse the relationship of Vitamin D and Parathyroid hormone levels 
to osteoporosis in these patients. 
 
 
3.To evaluate other risk factors that may contribute to osteoporosis in 
patients with Chronic Liver Disease 
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REVIEW OF LITERATURE 
 
Chronic Liver disease is a common problem that is associated with 
increased mortality and poorer health-related quality of life, regardless of 
the underlying etiology. One of the morbidities associated with chronic  
liver disease is metabolic bone disease. There is an increased incidence of 
both osteomalacia and osteoporosis in patients with chronic liver disease. 
 
Prevalence and Clinical Importance: 
 
The reported prevalence of osteoporosis among patients with chronic 
liver disease ranges from 20% to 100%, depending on patient selection and 
diagnostic criteria. The pathogenesis is unclear and likely is multifactorial. 
Regardless of the etiology of bone disease in these patients, they have an 
increased incidence of bone pain and fractures, a major source  of   
morbidity. There is also a further significant increase in the risk of fractures 
following liver transplantation for end stage chronic liver disease. 
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OSTEOPOROSIS AND BONE MINERAL DENSITY: 
 
Definition and diagnosis of osteoporosis 
The definition of osteoporosis is centered on measurement of bone 
mineral density (BMD) and identifies the majority of patients who will sus-
tain a fracture in the future. It is defined in women as a BMD in the hip 
and/or spine that is 2.5  standard deviations (SDs) or more below the young 
adult mean value (T score less than −2.5). A similar cut off may be used in 
men although the evidence to support this is less secure than in women. Os-
teopenia is defined as a T score between −1 and −2.5.  
Although a T score is used to define osteoporosis (World Health Organiza-
tion, 1994) BMD can also be compared with age matched controls. A z 
score of −2 defines a BMD 2 SDs below the mean value of age matched 
controls. 
Relationship between BMD and fracture risk 
Prospective studies have shown that the risk of fracture increases 
progressively with decreasing BMD, the risk of fracture increasing two to 
threefold for each SD decrease in BMD.
4 
BMD has a high specificity for 
fracture but a low sensitivity and so has not been advocated for population 
screening. 
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Measurement of bone mineral density 
Bone density can be measured at a number of skeletal sites,  
including the lumbar spine and femoral neck, using dual energy X ray  
absorptiometry (DEXA). Lumbar spine measurements are unreliable in the 
elderly due to the presence of osteophytes, extra skeletal calcification, and  
vertebral and/or spinal deformity. Ultrasound measurements of the os calcis 
have been shown to predict fracture risk in postmenopausal women but  
diagnostic thresholds have not been established and so this cannot yet be 
recommended in clinical practice. 
Clinical risk factors 
Bone mass increases through childhood reaching a peak in the third 
decade and then after 40 years declines in both sexes but more rapidly in 
women, accelerating after the menopause. Peak bone mass is determined by 
genetic factors, hormonal status, diet, and exercise, and men have a higher 
peak bone mass than women. Thus irrespective of other factors, the  
incidence of osteoporosis increases in the elderly as age related bone loss is 
a normal phenomenon. 
The risk of fracture is determined not only by bone density but also 
by trabecular architecture, skeletal geometry, bone turnover, and  
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non-skeletal risk factors such as postural instability and the propensity for 
falls. 
Risk factors for osteoporosis and subsequent fracture, irrespective of 
the presence of chronic liver disease, include low body mass index (<19 
kg/m
2
), alcohol excess, prolonged corticosteroid therapy (prednisolone  
5 mg/day for more than three months), physical inactivity, previous fragili-
ty fracture, early maternal hip fracture (<60 years), hypogonadism, and 
premature menopause (age <45 years). 
When assessing the risk of osteoporosis in individuals with liver  
disease it is important to realize that these patients often have a low body 
mass index, may drink excessive amounts of alcohol, and may be  
receiving corticosteroids. Certain liver diseases such as primary biliary cir-
rhosis occur predominately in postmenopausal women and cirrhosis is 
more prevalent with increasing age. 
Biochemical markers of bone disease: 
There is an association between bone turnover and fracture risk,  
independent of BMD. 
Biochemical markers of bone turnover can be divided into two 
groups: markers of resorption and markers of formation. The principal 
markers of bone formation are the procollagen propeptides of type 1  
 
 
23 
collagen, osteocalcin, and the bone isoenzyme of alkaline phosphatase. The 
latter is less useful in chronic liver disease as it is difficult to measure  
accurately in the presence of high values of liver alkaline phosphatase. 
The most widely used markers of bone resorption are: urinary  
excretion of deoxypyridinoline, pyridinoline, and type 1 collagen cross 
linked N-telopeptide. These are usually expressed in relation to urinary cre-
atinine. Urine hydroxyproline is a poor marker and now rarely used. 
These serum bone markers may prove useful in assessing response to 
treatment in the future in individuals without chronic liver disease.  
However, as the levels are affected by the extent of hepatic fibrosis and 
none of these markers has been studied in patients with chronic liver  
disease, they cannot yet be recommended as a means of assessing bone loss 
and the risk of fracture in cirrhotic patients. 
PATHOGENESIS OF BONE LOSS IN CHRONIC LIVER DISEASE 
Osteoporosis 
Bone loss occurs as a result of increased bone turnover and/or remodeling 
imbalance. The latter may be due to reduced formation or increased  
resorption or a combination of the two. Some studies have shown  
increased bone resorption, even in the absence of osteoporosis, in the pres-
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ence of chronic liver disease whereas most others have shown  
decreased bone formation.
5,6
 
Osteomalacia 
Osteomalacia can also lead to low BMD. The classical biochemical 
changes are hypocalcaemia, hypophosphatemia, increased parathyroid 
hormone, and elevated bone alkaline phosphatase although serum  
calcium and phosphate are often normal. Hepatic osteomalacia, as  
defined by strict histomorphometric criteria, is rare.
7, 8
 .In a recent study of 
60 patients awaiting liver transplantation none had evidence of osteomala-
cia on bone biopsy (J E Compston, personal communication). 
Vitamin D deficiency/insufficiency 
Vitamin D is obtained from endogenous skin synthesis which  
involves exposure to sunlight, leading to the production of cholecalciferol 
(vitamin D3). Ergocalciferol (vitamin D2) and vitamin D3 are also  
acquired from natural and fortified food. Vitamin D undergoes 25  
hydroxylation in the liver which is only impaired in the presence of  
severe chronic liver disease. Vitamin D insufficiency is associated with 
secondary hyperparathyroidism, increased bone turnover, and accelerated 
bone loss. As vitamin D deficiency becomes more severe, impaired bone 
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mineralisation leads to accumulation of osteoid which is a feature of  
osteomalacia. 
Many studies have shown low serum levels of 25-hydroxyvitamin D 
in patients with chronic liver disease
9,10
 and levels fall with disease  
progression in cirrhosis.
11
 Although malabsorption of 25-hydroxyvitamin D 
has been demonstrated in patients with chronic liver disease, this does not 
completely account for the low vitamin D levels seen in these  
patients. It is likely that both reduced exposure to UV light and dietary  
insufficiency account for vitamin D deficiency in the majority of cases. 
There is also impaired cutaneous synthesis of vitamin D in the presence of 
jaundice. 
Prevalence of osteoporosis and fracture 
There are no prospective studies addressing the fracture rate in  
patients with chronic liver disease and no good observational studies. Many 
studies have investigated the prevalence of osteoporosis, as defined by 
BMD measurements. However, in these studies different methodologies 
and different sites were used to assess BMD. The definition of  
osteoporosis also differed between studies and patients were selected  
using different criteria. 
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Patients with chronic liver disease also have other risk factors for  
osteoporosis related to their disease, such as hypogonadism, vitamin D  
insufficiency, excess alcohol consumption, corticosteroid use, and low 
body mass index. The proportion of patients with these risk factors also  
varies between studies. 
Cirrhosis 
Osteoporosis and fractures are more common in cirrhotics than in the 
normal population in the absence of confounding risk factors such as fe-
male sex, cholestasis, and excess alcohol. In a study of male cirrhotics with 
a viral etiology, half of the 32 patients were osteoporotic, defined as a T 
score of less than −2.5 at the lumbar spine or femoral neck. The mean Z 
score at the lumbar spine was −1.27 (1.6) g/cm2, indicating the wide  
inter individual variation in bone density even among this relatively  
homogeneous population of cirrhotics
2
 .In another study of 74 males with 
hepatitis B or C cirrhosis, osteoporosis in the lumbar spine, defined as a z 
score of less than −2, was seen in 20% and fractures in 6.7%, mean BMD 
being significantly lower than in healthy controls.
12
 The prevalence of  
osteoporosis is related to the severity of liver disease in cirrhosis.
6,13
In a 
study of 58 cirrhotic patients referred for liver transplantation, 43% had  
osteoporosis, defined by at least one vertebral fracture and/or a lumbar 
spine BMD more than 2 SDs below the mean value for normal subjects of 
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the same age (z score <−2.0). Alcoholics and those with more severe liver 
disease—that is, Child Pugh class C patients—had the lowest BMD.13 
Cholestatic liver disease: A high prevalence of osteoporosis has also been 
reported in individuals with cholestatic liver disease. 
Primary biliary cirrhosis: Many studies have evaluated BMD in  
patients with primary biliary cirrhosis (PBC).
14-21
 It is not clear whether  
osteoporosis occurs in early stage PBC where there is cholestasis without 
significant hepatic fibrosis. However, reduction in BMD is related to the 
severity of liver disease.
14-16
 
Not all patients with PBC will develop osteoporosis and the rate of 
bone loss varies between patients. In 25 patients with PBC and low BMD  
(z score <−2), spinal BMD fell by 3.5% over a six month  
period
17
 whereas in another study, 210 women with PBC with a range of 
bone densities, mean rate of bone loss was 2%/year.
16
 In a study of 36 PBC 
patients who were not osteoporotic (defined as lumbar spine BMD >0.800 
g/cm
2
) at the start of a three year follow up, 11 subsequently  
became osteoporotic and had a higher annual bone loss than the other 25 
patients.
19
 In contrast, in a retrospective study of 225 patients with PBC, 
following on from an earlier study,
22
 of the 46% with late stage disease 
(stage 3/4) who had repeated BMD measurements, only one patient  
developed osteoporosis (defined as a z score <−2) during a mean follow up 
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of 10 years (D Jones, personal communication). In contrast with  
osteoporosis, osteomalacia is rarely seen in PBC.
20
 
Other factors that have been associated with osteoporosis in PBC include 
disease duration and degree of cholestasis, the latter reflecting the stage of 
liver disease. In a small study of 20 PBC patients, seven (35%) of whom 
were osteoporotic, osteoporosis was associated with longer  
duration of disease, intestinal calcium malabsorption, and  
postmenopausal state.
18
 
Although studies have suggested that cholestasis itself is a risk factor 
for osteoporosis, this may just be a reflection of the coexistence of cirrhosis 
with severe cholestasis as ursodeoxycholic acid, which improves  
cholestasis, has no effect on BMD. In a study of 88 female PBC patients, 
50 treated with ursodeoxycholic and 38 controls, there was no overall 
change in BMD in either group over a three year period.
15
 
Primary sclerosing cholangitis 
Individuals with primary sclerosing cholangitis (PSC) have multiple risk 
factors for osteoporosis. Patients may be cirrhotic as well as cholestatic and 
may also have been taking corticosteroids for many years for  
coexistent inflammatory bowel disease. 
 
 
29 
In a study of 81 patients with PSC followed up for five years,  
overall BMD of the lumbar spine was lower than age and sex matched  
controls.
23
 Those patient who had fractures were older, had a longer  
duration of inflammatory bowel disease, and more advanced liver  
disease. The incidence of osteoporosis (defined as a T score <−2.5)  
increased with worsening liver disease and 40% were osteoporotic at the 
time of liver transplantation and so at increased risk of post-transplant  
fracture. 
Non-cholestatic non-cirrhotic liver disease 
The prevalence of osteoporosis in non-cirrhotic liver disease  
patients who are not cholestatic or hypogonadal is unknown. Studies that 
have included such patients suggest that cirrhosis is the major  
independent risk factor for osteoporosis and fracture. 
In a study of 115 patients with chronic liver disease, of whom 20% 
were cholestatic, 36% alcoholic, 52% cirrhotic, and 18% on more than 7.5 
mg/day of prednisolone, 29% were found to have osteoporosis,  
defined as a Z score of less than −2. Mean age of the patients was 49 years 
(range 20–70). Between 12% and 18% had spinal fractures and  
peripheral fractures were more common among alcoholics. Both fractures 
and osteoporosis were more common in cirrhotics than non-cirrhotics and 
hypogonadal patients. Multiple regression analysis showed age, cirrhosis, 
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and hypogonadism to be predictive of osteoporosis in the lumbar spine. 
Hypogonadism, low BMD, and severity of liver disease were predictive of 
spinal fracture.
24
 
In a further study of 133 individuals with chronic liver disease, 24% 
alcoholic and 36% cirrhotic, the prevalence of lumbar spine  
osteoporosis varied between 16% and 50% (defined as a z score of less than 
−2). The highest rates were observed in cirrhotics and PSC patients. In a 
group of 19 non-cirrhotic patients with chronicactive hepatitis, 21% were 
osteoporotic but 50% of the group were taking corticosteroids.
25
 
Alcohol 
Alcohol is an independent risk factor for osteoporosis, alcoholism 
being associated with a 2.8-fold increase in the risk of hip fractures. In 
men, excess alcohol, irrespective of cirrhosis or low testosterone levels, is a 
risk for osteoporotic fractures.
29-36
 In a study of 76 men drinking more than 
27 units/day for more than 24 years, only 22% of whom had  
abnormal hepatic histology, lumbar spine BMD was lower than in age 
matched controls. Thirty per cent had vertebral compression fractures  
although only 4% were symptomatic.
34
 In a further study of 58 male  
non-cirrhotic drinkers, osteopenia was seen in 23% drinking >10 units/day 
and cumulative alcohol intake was inversely related to BMD.
35
 In women, 
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excess alcohol in the absence of hypogonadism and cirrhosis is not  
associated with osteoporosis.
36
 
MANAGEMENT 
 Introduction 
There are only a few small randomised controlled trials examining 
the role of intervention in preventing osteoporosis and reducing  
subsequent fractures in chronic liver disease. Most of the studies are 1–3 
year intervention studies in patients with PBC, not all of whom were  
cirrhotic. None of the studies was adequately powered to assess reduction 
in fracture rate as an end point . 
Calcium and vitamin D 
In elderly women living in sheltered accommodation, combined  
calcium and vitamin D supplementation reduces the risk of hip and other  
non-vertebral fractures. 
The role of calcium and vitamin D in preventing osteoporosis and 
fracture in chronic liver disease is unclear. In a cross sectional study of 55 
patients with PBC who were all taking adequate dietary calcium and  
vitamin D or who had been supplemented if deficient, mean BMD was 8% 
lower than in age and sex matched controls.
14
 In another small  
retrospective study in PBC, vitamin D3 and calcium supplementation did 
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not lead to a significant increase in BMD over baseline in the treated 
group.
42
 In the absence of larger studies on the effect of vitamin D  
supplementation on BMD it seems reasonable to recommend correction of 
vitamin D insufficiency with an oral daily dose of 800 IU of vitamin D3 and 
1 g of calcium. 
Osteomalacia has been shown to respond to treatment with oral or  
parenteral vitamin D or oral alfacalcidol.
46
 The role of high dose vitamin D 
in preventing osteoporosis and fractures is unclear and the efficiency of  
vitamin D absorption in the setting of chronic liver disease has been  
poorly studied. However, in one non-randomised controlled study in  
alcoholic cirrhotics with low BMD and low serum levels of 25  
hydroxyvitamin D, oral supplementation with 50 000 IU of vitamin D2 or 
20–50 μg of 25-OH vitamin D did increase BMD over baseline values in 
the treated group.
10
 
Hormone replacement therapy 
HRT is given as sequential combination therapy, continuous  
combination therapy, or oestrogens alone in women who have had a  
hysterectomy. In patients with chronic liver disease HRT can be given 
 safely.
47,48
 It should be given, where possible, via the transdermal route as  
physiological blood oestrogen levels can be achieved without exposing the 
liver to high levels of conjugated oestrogens. Transdermal oestradiol should 
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be used at a dose of 50 μg/day, equivalent to 2 mg daily of oral oestradiol. 
Unopposed oestrogens can be given to patients who have had a  
hysterectomy. Sequential or continuous combination therapy of oestrogens 
followed by progestogen should be given to women who have a uterus as 
this protects against endometrial hyperplasia. In women who  
cannot tolerate monthly bleeding, continuous combination therapy can be 
given providing that the patient has been free of bleeding for a year and is 
aged over 51 years. 
In general, in those women in whom it is indicated, the  
recommended duration of HRT is 5–10 years. However, the risk of  
osteoporosis in chronic liver disease continues beyond 10 years and the  
optimal duration of therapy has not been defined. The decision to  
continue HRT beyond 10 years has to be made on an individual basis in 
view of the increased risk of breast carcinoma after 5–10 years of  
therapy. 
In individuals with secondary amenorrhea, for example patients with 
autoimmune chronic active hepatitis, hypogonadism can be treated using 
the oral contraceptive pill or combination HRT. The former  
contains ethinyl oestradiol which is less degradable than oestradiol and so 
may be more hepatotoxic. 
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HRT in postmenopausal women without chronic liver disease has 
been shown to increase BMD in the lumbar spine and other 
sites.
49
 Observational studies, which may overestimate the benefits of HRT, 
show that oestrogen, also lowers the rate of veterbral and  
non-vertebral fractures in osteoporotic postmenopausal women.
50
 There are 
also a few small prospective studies showing that HRT reduces  
vertebral and non-vertebral fracture.
51-54
 
Few studies have examined the effect of HRT on BMD and  
fracture rates in postmenopausal or hypogonadal women with chronic liver 
disease. In a small retrospective study of 16 postmenopausal patients with 
PBC, oestrogen replacement resulted in a significant increase in BMD 
compared with untreated patients at one year and there was no  
evidence of worsening cholestasis.
42
 Long term controlled studies are need-
ed to assess the effect of HRT on BMD and fracture rates in  
hypogonadal women with chronic liver disease. 
Testosterone 
Testosterone replacement in hypogonadal men without chronic  
liver disease leads to increases in BMD.
55
 The role of testosterone in  
eugonadal men is still under evaluation. In a small study of 23 men with 
fractures, testosterone given for six months resulted in an increase in spinal 
BMD.
56
 In a trial of testosterone in patients with corticosteroid  
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induced osteoporosis, some of whom were hypogonadal, there was also a 
significant increase in spinal BMD.
57
 
There are no studies of the effects of testosterone replacement in  
patients with chronic liver disease on BMD and the subsequent fracture 
risk. Although hypogonadism is reported in male cirrhotics with chronic 
liver disease and male patients with end stage liver disease being assessed 
for liver transplantation, the overall prevalence is unknown.
12,13,58
 
In patients with chronic liver disease an increase in testosterone  
binding globulin levels may occur and total serum testosterone levels may 
overestimate free testosterone. Total testosterone should therefore be  
expressed in relation to testosterone sex hormone binding globulin (SHBG) 
levels if free testosterone levels cannot be measured. 
One concern about restoring testosterone levels to normal in  
cirrhotics is that this might increase the risk of hepatocellular carcinoma. 
Cirrhotics have relatively high oestrogen levels and male sex is a major risk 
factor for hepatocellular carcinoma. As the relative risk of inducing  
hepatocellular carcinoma in relation to testosterone levels is not known, the 
potential risk/benefit must be discussed with individuals before 
 starting replacement therapy. Transdermal testosterone is the preferred 
route of administration in cirrhotic patients as it leads to stable  
testosterone concentrations within the normal range, therefore avoiding  
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exposure of the liver to the high levels seen with oral preparations, depot  
injections, or implants. 
 Bisphosphonates 
Bisphosphonates include oral alendronate, cyclical etidronate, and  
risedronate. In postmenopausal women with osteoporosis without liver  
disease, bisphosphonates increase BMD and decrease the incidence of  
vertebral and non-vertebral fractures.
59
 There are no comparative studies 
comparing the different preparations. Oral alendronate, which can be  
given as a daily dose of 10 mg or as a 70 mg dose weekly, may cause  
oesophageal ulceration and so should be avoided in patients with cirrhosis 
who may have portal hypertension and oesophageal varices because of the 
potential to precipitate a variceal haemorrhage. No adverse effects on the 
oesophageal mucosa have been reported with risedronate in clinical trials 
although post marketing data are not yet available.
60
 
Cyclical etidronate has been given safely for up to seven years. 
However, there is some theoretical concern about the use of long term  
bisphosphonates as although they increase BMD they may also increase 
bone mineralisation with potential adverse effects on bone strength. 
Bisphosphonates are also effective in preventing corticosteroid  
induced osteoporosis in patients with PBC. In a randomised placebo  
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controlled trial of 12 patients with late stage PBC who were given 10 mg of 
prednisolone for >1 year and who had normal z scores at baseline,  
cyclical etidronate prevented the fall of 3 SD in BMD which was seen in 
untreated patients.
37
There are no long term studies of  bisphosphonates in 
preventing fractures in individuals with chronic liver disease. 
Bisphosphonates should be taken on an empty stomach in the  
morning, 0.5–2 hours before consumption of food and other drugs, and at a  
different time to calcium supplements as calcium binds and inactivates  
bisphosphonates. 
Anabolic steroids 
These drugs can cause abnormal liver biochemistry and should be 
avoided in patients with chronic liver disease 
Combination therapies 
The role of combination therapy in managing postmenopausal  
osteoporosis is a current area of interest. In a small non-randomised  
controlled study of patients with PBC, whose lumbar spine BMD was less 
than 0.8 g/cm
2, three years of treatment with 0.5 μg daily of calcitriol  
(1, 25 dihydroxyvitamin D), 1.5 g of calcium, and 40 Medical Research 
Council units of carbocalcitonin, given subcutaneously three times a week, 
resulted in an improvement in bone density in the treated group compared 
with baseline values.
19
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MATERIALS AND METHODS 
Study Design: 
Cross-Sectional Study. 
Study Population: 
55 patients with decompensated non cholestatic chronic liver  
disease (Alcohol and Hepatitis B and C as primary etiology) of any age 
group and of either sex admitted in medical ward in GGH, Chennai were 
taken into study irrespective of their primary complaints. The study was 
done from May 2010 to September 2010. 
Inclusion Criteria: 
Patients with decompensated chronic liver disease with Alcoholic 
liver disease and Hepatitis B and C as the primary etiology.  Chronic liver 
disease is defined as liver disease with duration of atleast 6 months and 
with a diagnosis based on biochemical, serological and histopathological 
investigations. 
Exclusion Criteria: 
Patients with decompensated chronic liver disease with impaired re-
nal function and postmenopausal women and those with cholestatic  
liver disorders. 
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Ethical Clearance: 
Obtained. 
Informed Consent: 
Obtained from all patients. 
Methodology: 
A total of 55 patients were identified  according to the above criteria 
and were included in the study.  
A questionnaire prepared noted the age, sex, address, primary  
complaints, jaundice, abdominal distension, swelling of legs, altered  
sensorium, hematemesis, melena ,easy fatiguability, fever, skin rash 
,altered sleep pattern ,loss of weight and appetite and decreased urine  
output and presence of dyspnea and abdominal pain. Other relevant history 
like history of drug intake, past medical history, personal history  and  
sexual history was  obtained.  
Clinical examination included a detailed examination from head to 
foot, examination of cardiac, respiratory, GI tract, and nervous system. Per 
rectal in both male and female patients and pelvic examination in  
females was done. 
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Laboratory Investigations: 
The following investigations are done in all patients during their first  
visit: 
Serum urea, creatinine 
Blood sugar, 
Complete blood count, including red cell indices, ESR, 
Liver function test, 
PT/INR, 
chest X-ray,  
ECG, 
USG – Abdomen, 
UGI Scopy, 
HbsAg, 
Anti-HCV, 
Serum calcium, 
Serum phosphorous, 
Serum Vitamin D3, 
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Parathyroid hormone, 
DEXA BMD Value, 
In selected patients the following investigations were done for the diagnosis 
Liver biopsy. 
Table 5: 
S.NO Parameter Method  
1. Complete blood 
count 
Automated flow cytometry 
2. ESR Westegren method 
3. urea GLDH/urease 
4. creatinine Picrate method 
5. Serum albumin Bromocresol green 
6. bilirubin Calorimetric endpoint diazo  
7. Total protein Biuret method 
8. Intact PTH Chemi luminescent Immuno Assay 
9. 25-OH VITAMIN D3 Bidirectionally interfaced Chemi Lu-
minescent Immuno Assay 
10. Serum calcium Photometry assay 
11. Serum phosphorous Enzyme linked immunosorbent  assay 
12. ANA Enzyme linked immunosorbent assay 
13. HBsAg C.L.I.A 
14. Anti  HCV ELISA 
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Measurements of bone mineral density 
 
Bone mineral density (BMD; g/cm2) of the lumbar spine was  
measured by dual  Energy X-ray absorptiometry (DXA)at baseline.BMD 
was expressed as  Score. The WHO´s definition for osteoporosis was  
applied to classify individuals as either osteoporotic or not. 
Statistical Analysis: 
SPSS 13 and Excel were used for statistical analysis. Univariate  
analysis was done with Fisher’s exact test and Chi square test for discrete  
variables and Wilcoxon rank sum test for continuous variables. Logistic  
regression analysis was done for the risk factors which were found to have 
a statistically significant association by Univariate analysis to find the  
independent risk factors associated with osteoporosis.  
Limitations: 
Small number of study subjects especially females 
Chronic liver disease patients only with Alcoholic liver disease       
and hepatitis B and c were selected for the study. 
 
Conflicts of interest: 
None 
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Table 6:  
NORMAL VALUES 
Hemoglobin M: 13.3 – 16.2gms% F: 12.0 – 15.8gms% 
PCV M: 38.8 – 46.4 35.4 – 44.4 
Total Count 3.54 – 9.06x 103/mm3 
Platelet Count 165 – 415 x 103/mm3 
MCV 80 – 100 Fl 
MCHC 32.3 – 35.9g/dL 
MCH 26.7 – 31.9 pg/cell 
ESR M: 0 -15mm/hr F: 0-20mm/hr 
Reticulocyte count M: 0.8 – 2.3% F: 0.8 – 2.0 % 
Creatinine  M: 0.6 – 1.2mg/dl F: 0.5 – 0.9mg/dl 
BUN 7 – 20 mgs/dl 
Total Bilirubin 0.3 – 1.3 mgs/dl 
Direct Bilirubin 0.1 – 0.4 mgs/dl 
SGOT 12 – 38 U/L 
SGPT 7 – 41U/L 
Se.Alkaline phosphatase 33 – 96 U/L 
Total Protein 6.7 – 8.6 gms/dl 
Se.Albumin 3.5 – 5.5 gms/dl 
PTH 15-65 pg/ml 
25 OH VITAMIN D3 11.1-42.9 ng/ml 
Serum calcium 8.7-10.2 mg/dl 
Serum phosphorous 2.5-4.3 mg/dl 
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RESULTS & OBSERVATIONS 
STUDY POPULATION CHARACTERISTICS: 
Among 55 patients included in our study, 41 (74.54%) patients were 
male, and 14(25.45%) patients were female. 
The Mean Age of the patients included in the study is 50.16 mean 
years, with S.D. of 11.79 years, with Mean Age of males being 51.73 years 
and females were 39.35 years. 
TABLE-7: AGE AND SEX DISTRIBUTION OF STUDY POPULA-
TION 
Age Group Males Females Total Percentage 
20-30 0 3 3 5.45% 
30-40 3 2 5 9.09% 
40-50 12 9 21 38.18% 
50-60 14 0 14 25.45% 
60-70 11 0 11 20.00% 
Above 70 1 0 1 1.82% 
Total 41 14 55 100.00% 
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Most of our patients are in the age group are in the range of 40-50 years age 
group, and most are males owing to increased prevalence of alcoholism 
among males . 
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TABLE-8: DISTRIBUTION OF PATIENTS AS PER ETIOLOGY 
ETIOLOGY MALE FEMALE TOTAL % 
 
ALD 
 
19 
 
3 
 
24 
 
40% 
 
HEPATITIS B 
 
17 
 
4 
 
21 
 
38.18% 
 
HEPATITIS C 
 
8 
 
4 
 
12 
 
21.81% 
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TABLE-9 DISTRIBUTION OF PATIENTS AS PER CHILD PUGH 
SCORE 
 
CHILD SCORE TOTAL NUMBER PERCENTAGE 
A 15 27.27% 
B 21 38.18% 
C 19 34.54% 
 
 
 
 
 
 
27% 
38% 
35% 
CHILD PUGH CLASSIFICATION 
A B C
 
 
50 
DEMOGRAPHICS AND CLINICAL PROFILE OF PATIENTS 
 
Age                                    50.16; 11.79 
Gender (Female)     25.45% 
Alcoholism      43.63% 
Bilirubin      5.16; 4.48 
AST       94.35; 59.50 
ALT       86.81; 44.91 
PT       1.71; 0.58 
ALBUMIN      3.34; 0.37   
ASCITES      78.18% 
CALCIUM      8.97; 0.94 
 
 
 
Numbers indicate percentage of cases for dichotomous variables and mean 
and standard deviation for continuous variables. 
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PREVALENCE AND RISK FACTORS FOR OSTEOPOROSIS 
IN CLD 
 
The prevalence of osteoporosis in the study group was 29.09% and 
the prevalence of osteopenia in the study population was 38.18%. Only 4 
out of the 16 patients with osteoporosis had evidence of osteoporosis in 
their x ray of the lumbosacral spine (23.55%). 
 
Table 6 compares the prevalence of osteoporosis in the alcoholic liv-
er disease group and the post hepatitis group. 
 
*
Chi square test and Fisher exact t test 
The difference in the prevalence of osteoporosis in the Alcoholic liv-
er disease group and in the hepatitis group was statistically insignificant. 
 
 ALD HEPATITIS P VALUE 
 
ALL 
 
10(38.46%) 
 
6(20.68%) 
 
0.147
* 
 
MALES 
 
8(36.36%) 
 
5(17.24%) 
 
0.490
* 
 
FEMALES 
 
2(50%) 
 
1(10%) 
 
0.210* 
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UNIVARIATE ANALYSIS OF THE RISK FACTORS ASSOCIATED 
WITH OSTEOPOROSIS: 
1) AGE  
Age group Osteoporosis Normal Total 
Age<50 8.0(8.964) 21.0(20.036) 29 
Age>50 9.0(8.036) 17.0(17.964) 26 
Total 17 38 55 
 
Degrees of Freedom = 1 
Pearson Chi-Square Statistics = .317 
P-Value = 0.5733052076671328 
2) SEX 
 
 
 
 
 
 
Degrees of Freedom = 1 
Pearson Chi-Square Statistics = .535 
P-Value = 0.46470951095672686 
 
 
Sex Osteoporosis Normal Total 
Male 13.0(11.927) 28.0(29.073) 41 
Female 3.0(4.073) 11.0(9.927) 14 
Total 16 39 55 
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3) TOTAL BILIRUBIN 
Results of Two Independent Sample Wilcoxon Rank Sum Test: 
 
BILIRUBIN OSTEOPOROSIS NORMAL 
SAMPLE SIZE 16 39 
MEAN 8.254 3.716 
 
Z score:  3.083 
Two sided p value: 0.002 
 
4) ALBUMIN 
Results of Two Independent Sample Wilcoxon Rank Sum Test: 
 
ALBUMIN OSTEOPOROSIS NORMAL 
SAMPLE SIZE 16 39 
MEAN 3.106 3.413 
 
Z score: -2.539 
Two sided p value: 0.011 
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5) PROTHROMBIN TIME 
Results of Two Independent Sample Wilcoxon Rank Sum Test: 
 
PT/INR OSTEOPOROSIS NORMAL 
SAMPLE SIZE 16 39 
MEAN 2.194 1.508 
 
Z score:  3.456 
Two sided p value: 0.001 
 
6) CALCIUM 
Results of Two Independent Sample Wilcoxon Rank Sum Test: 
 
CALCIUM OSTEOPOROSIS NORMAL 
SAMPLE SIZE    16   39 
MEAN    9.094 9.208 
 
Z score: 0.454 
Two sided p value: 0.650 
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8) PTH 
Results of Two Independent Sample Wilcoxon Rank Sum Test: 
 
PTH OSTEOPOROSIS NORMAL 
SAMPLE SIZE 16 39 
MEAN 55.516 46.229 
 
Z score: 1.835 
Two sided p value: 0.067 
9) VITAMIN D3 
Vitamin D3 Osteoporosis Normal Total 
Low 14.0(7.564) 12.0(18.436) 26 
Normal 2.0(8.436) 27.0(20.564) 29 
Total 16 39 55 
 
Degrees of Freedom = 1 
Pearson Chi-Square Statistics = 14.649 
P-Value = 0.00012 
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10) CHILD PUGH SCORE 
Results of Chi-Square Test for Independent or Homogeneity 
 
Child Class Osteoporosis Normal Total 
A 3.0(4.491) 10.0(8.509) 13 
B 3.0(7.600) 19.0(14.400) 22 
C 13.0(6.909) 7.0(13.091) 20 
Total 19 36 55 
 
Degrees of Freedom = 2 
Pearson Chi-Square Statistics = 13.213 
P-Value = 0.0013512690533349359 
Prevalence of osteoporosis in Child Classes A, B and C 
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FIGURE: BOX PLOT OF VIT D3 LEVELS IN NORMAL, OSTEOPO-
ROTIC AND OSTEOPENIC INDIVIDUALS. 
 
 
FIGURE 3: VITAMIN D3 LEVELS ACROSS BMD MEASUREMENTS 
Logistic Regression analysis was done to find out Independent risk factors 
for osteoporosis. The results are given in the table below . 
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Independent risk factors for osteoporosis. 
Table 10: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For continuous variables the odds ratio indicates the risk of osteoporosis when the mag-
nitude of the variable changes by one standard deviation. For dichotomous variables the 
odds ratio indicates the risk when the variable changes from 0 to 1. NS=not significant 
 
By logistic regression model it was found that only Vitamin D defi-
ciency , total bilirubin , Prothrombin time and Child class C were inde-
pendent risk factors for prediction of osteoporosis in decompensated chron-
ic liver disease patients. 
Risk factor Odds ratio Confidence inter-
val 
p value 
Sex 0.473 0.114-1.968 NS 
Vitamin D3 16.667 3.28-84.48 0.001 
PTH 1.035 0.994-1.077 NS 
Bilirubin 1.146 1.001-1.311 0.048 
INR 5.136 1.658-15.907 0.005 
Albumin 0.508 0.134-1.925 NS 
SGOT 1.004 0.992-1.017 NS 
Calcium 0.439 0.189-1.018 NS 
Phosphorous 1.775 0.796-3.956 NS 
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Figure 4: Linear regression curve shows low vitamin D3 levels in the oste-
oporotic BMD range. 
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DISCUSSION 
Osteoporosis is a common condition and the highest incidence rates 
for osteoporotic fractures are found in the old and in postmenopausal  
women. The prevalence of osteoporosis is highly dependent upon age and 
gender. Like Chronic kidney disease liver disease also predisposes to  
osteoporosis due to numerous causes. 
The prevalence of osteoporosis in the cohort was 29.09%, and the 
prevalence of osteopenia was 38.18%.Only 4 patients had evidence of  
osteoporosis in their X ray and none of the patients had any fractures. This 
prevalence is similar to the prevalence in a study done by Ormarsdóttir et al 
in 72 patients with chronic liver disease of  varied etiology61 . Similarly in a 
study done by Ghizlane Wariaghli et al. the prevalence of osteoporosis was 
found to be 43% in a cohort of 64 patients with chronic liver disease  
(Primary biliary cirrhosis and post hepatitis)62. The prevalence among males 
was 36.36% among ALD group and 17.24% among hepatitis group. The 
prevalence among females was 50% among ALD group and 10% among 
hepatitis group. The difference was statistically insignificant. 
The difference in the prevalence of osteoporosis in the Alcoholic  
liver disease group and in the hepatitis group was statistically insignificant. 
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The size of our patient cohort was limited by several factors. The  
prevalence of CLD is low in females and our patient cohort was not a  
randomised  sample from the population and included patients admitted in 
a tertiary care hospital. Only three main causes of Chronic liver disease 
were included in our study and it included patients with alcoholic liver  
disease and hepatitis B and hepatitis C. These limitations, however, can  
also be found in previously published studies. The reported prevalence  
figures for osteoporosis in patients with CLD range from 9 to 53. These  
differences in reported prevalence can probably explained by different  
patient selection factors, different techniques of bone mass measurement 
and definition of osteoporosis. 
We found a high prevalence rate, 65%, in patients classified as 
Child-Pugh C and only 17% in patients classified as Child Pugh A and B 
group put together. This association was statistically significant.  
(P value=0.001). Similar results were obtained in the study by Ormarsdóttir 
et allfound a high prevalence rate, 42%, in patients classified as Child-Pugh 
B and C compared with 25% in the Child-Pugh A group. 
Increased prothrombin time (as amarker of liver function) was an  
independent risk factor for osteoporosis. This issupported by other studies 
that have found the highest prevalence of metabolic bonedisease in patients 
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with advanced liver disease (25, 31, 41, 46, 54) whereas in earlierstages of 
liver disease no evidence of bone disease has been found [41, 125]. 
Apart from belonging to Child-Pugh C and prothrombin time,  
patients with low 25(OH) VIT D3 levels had the most profound reduction 
in BMD and 61% of these patients had osteoporosis. Furthermore, in the 
logistic regression analysis, we found low Vitamin D3 levels to be  
an independent risk factor for osteoporosis.30% of these patients had  
osteopenia which is a forerunner of osteoporosis. These findings correlate 
with the study by Arteh J et al who found Vitamin D deficiency to be  
universal among patients with Chronic liver disease  (92% of patients had  
vitamin D deficiency  and one third of these patients had severe vitamin  
D- deficiency). In addition to its role in calcium metabolism, vitamin  
D derivatives may be involved in cell proliferation, differentiation, and  
immunomodulation [13]. Vitamin D inhibits certain types of matrix  
metalloproteinases (MMP, a family of zinc-dependent endoproteinases that 
are involved in degradation of extracellular matrix components) and  
induces their inhibitors [14]. Consequently, vitamin D deficiency has been 
associated with increased circulating MMP2,9, a situation that can be  
corrected with vitamin D supplementation [15]. Other effects of vitamin D 
include suppression of proliferation of fibroblasts and increased collagen 
production [16]. These data are relevant to chronic liver disease. Even 
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though hepatocytes are the major source of MMPs and tissue inhibitors, 
their production is not affected by the presence of cirrhosis [17]. Therefore, 
vitamin D deficiency in patients with chronic liver disease (CLD) can lead 
to progression of hepatic fibrosis. Moreover, inhibition of MMPs has been 
shown to provide protection from hepatic ischemic injury. 
Similarly an association between low albumin levels and  
osteoporosis was found which was statistically significant (p value 0.011). 
The mean albumin level among patients with osteoporosis was 3.106 and it 
was 3.413 among patients without osteoporosis. Similar results are  
obtained with prolonged prothrombin time. 
All other variables like AST, ALT, ALP, Calcium, PTH, PO4 levels 
were not found to have a statistically significant association with  
osteoporosis. 
By Logistic regression analysis Low Vitamin D3 levels, prolonged 
prothrombin time, Total bilirubin and Child class C were found to be  
independent predictors of osteoporosis. 
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LIMITATIONS OF THE STUDY 
The major limitation of our study is small number of subjects we 
have included in our study and large number of males compared to the  
females. This is because of the increased prevalence of Chronic liver  
disease among males. No control arm was available to compare the  
prevalence of osteoporosis. In DEXA scan only T score was used and not Z 
score which is based on age and sex matched controls. Being a tertiary care 
centre, patients with more severe disease are often referred than patients 
with mild disease. Even though the prevalence of  osteoporosis was found 
out the true incidence of fractures in patients with chronic liver disease is 
not known and a prospective follow up study is needed to address this  
issue. 
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CONCLUSIONS 
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CONCLUSIONS: 
 
 Chronic Liver disease is a common problem that is associated with 
increased  mortality and poorer health-related quality of life,  
regardless of the  underlying etiology.  
 
 One of the morbidities associated with chronic liver disease is  
metabolic bone disease. 
 
 The prevalence of osteoporosis is very high among Chronic liver  
disease  patients .29.09% in this study. 
 
 Serum Vitamin D3 levels,  Prolonged prothrombin time , Serum  
albumin  levels Child C group ( severity of chronic liver disease) and 
serum bilirubin  levels correlated strongly with low BMD levels. 
 
 There was no significant correlation between PTH , serum calcium , 
age , sex and cause of chronic liver disease with osteoporosis. 
 
 Serum Vitamin D3 levels , Prolonged prothrombin time and severity 
of  chronic liver disease were independent predictors of osteoporosis 
as per  logistic regression analysis. 
 
 Vitamin D deficiency was almost universal and serum levels varied 
as per  the severity of the chronic liver disease. 
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 Patients with chronic liver disease, should also have BMD  
performed. BMD measurement is not indicated routinely in other  
patients with liver disease as there is no evidence at present that os-
teoporosis is more prevalent in patients  who are non-cirrhotic and 
not cholestatic but further controlled studies are needed. 
 
 Treatment of patients with osteoporosis or those with fragility  
fractures is a must. 
 
 Treatment options include Bisphosphonates, Calcitriol and  
Calcitonin. 
 
 Serum 25(OH) Vitamin D3 levels should be measured in all patients 
with  Chronic liver disease and supplementation  should be given if 
found low. 
 
 Vitamin D3 supplementation will retard the progression of chronic 
liver disease as it inhibits the MMP’s and suppresses the proliferation 
of fibroblasts 
 
 The prevalence of asymptomatic vertebral fractures in patients with 
chronic  liver disease is unknown and needs further study. 
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RECOMMENDATIONS: 
 
1) Hepatic osteodystrophy should be considered a distinct disease 
entity in patients with chronic liver disease similar to renal  
osteodystrophy. 
 
2) BMD and Vitamin D3 should be measured in all patients with  
decompensated chronic liver diseases. 
 
3) Treatment should be initiated in all patients with osteoporosis or 
those with fragility fractures. 
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FUTURE AREAS OF RESEARCH 
 
1)  a prospective study of the  prevalence of  fractures in patients 
with chronic liver disease; 
2) a study of the prevalence of osteoporosis in patients with all stag-
es of PBC compared with sex and age matched controls; 
3) a prospective study of the prevalence of hypogonadism in males 
with cirrhosis with and without osteoporosis; 
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Osteoporosis in Non cholestatic decompensated chronic 
liver disease and its co-relation with Vitamin D and 
Parathyroid hormone levels 
PROFORMA 
 
Name:          Age:       Sex:                       OP.NO: 
Address:                              Ph.No: 
  
Presenting Complaints: 
Jaundice:                                                                Abdominal distension:    
Swelling of legs:                                                    Altered sensorium: 
Hematemesis:                                                 Melena: 
Easy fatiguability:                                                  Fever: 
Purpura/Skin rash:                                                 Altered sleep pattern: 
Loss of  Wt:                                                           Loss of Appetite: 
Decreased urine output:                                         Dyspnea: 
Myalgia:                                                                 Back pain: 
Joint pain:                                                                
Abdominal pain:                                                     
Drug intake: 
Co-morbid Illness:  DM:        HT:    TB:      Cardiac illness: 
Menstrual h/o:  undue bleeding PV: 
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H/o previous treatment/ surgery/blood transfusion:  
H/o  high risk sexual behaviour: 
others if any: 
Personal History:            
Alcohol                   duration:                   frequency:                 quantity: 
Tobacco                  Pack years: 
 
EXAMINATION: 
Pallor:                                                            Jaundice:                               
Lymphadenopathy:                                        Cyanosis:                                     
Clubbing:                                                       Pedal edema:                                                               
Others: 
PR:                                                                 BP: 
CVS: 
RS: 
Abdomen: 
Genitals: 
CNS: 
Per rectal / pelvic examination: 
 
INVESTIGATIONS:  FOR ALL PATIENTS: 
 
CBC 
HB%:                 PCV:                  ESR:                      
TC:        P:      L:      E:     B:      M:        Platelets:                                
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RFT:   Bl sugar:                             Urea:                                Creatinine: 
 
LFT: Tot.bilirubin:                 Direct:                SGOT:            SGPT:             
Alkaline phosphatase:        
Total Protein:                                             Serum Albumin:      
 
PT/INR: 
 
X-RAY CHEST: 
 
X-RAY LS SPINE AND HIP JOINTS: 
 
ECG: 
 
USG-Abdomen: 
 
UGI Scopy: 
 
Viral markers                                  HbsAg:                    anti-HCV: 
 
Serum Calcium: 
Serum phosphorous: 
25(OH)Vitamin D3 : 
Parathyroid hormone: 
DEXA BMD VALUE OF LUMBAR SPINE: 
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CHILD SCORE : A/B/C 
 
INVESTIGATIONS:  IN SELECTED  PATIENTS 
Liver biopsy: 
 
FINAL ETIOLOGY : 
DISEASE SEVERITY: 
BMD SCORE OF LUMBAR SPINE: 
VITAMIN D AND PTH STATUS : 
 
  
PARAMETER 1 2 3 
Ascites absent Slight  moderate 
Hepatic encephalopathy 
 
none Grade 1-2 Grade3-4 
Bilirubin <2 2-3 >3 
Albumin  >3.5 2.8-3.5 <2.8 
PT 
    Secs over control 
    INR 
 
<4 
<1.7 
 
4-6 
1.7-2.3 
 
>6 
>2.3 
 
A:5-6 
B:7-9 
C:10-15 
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 PATIENT CONSENT FORM 
Study detail:  Osteoporosis in Non cholestatic decompensated chronic 
  liver disease and its co-relation with Vitamin D and 
 Parathyroid hormone levels 
Study centre  :             Institute of Internal Medicine, Madras Medical College, Chennai. 
Patients Name  : 
Patients Age  : 
Identification Number        : 
   Patient may check (     ) these boxes 
I  confirm that I have understood the purpose of procedure for the above study. I have the opportunity 
to ask question and all my questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical com-
mittee and the regulatory authorities will not need my permission to look at my health records, both in 
respect of current study and any further research that may be conducted in relation to it, even if I with-
draw from the study I agree to this access. However, I understand that my identity will not be revealed 
in any information released to third parties or published, unless as required under the law. I agree not to 
restrict the use of any data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from any 
deterioration in my health or well being or any unexpected or unusual symptoms. 
I hereby consent to participate in  this study. 
I hereby  give permission to undergo complete clinical examination and diagnostic tests including hema-
tological, biochemical, radiological tests. 
Signature/thumb impression:    
Patients Name and Address:                   place   date 
 
Signature of investigator :    
Study investigator’s Name :                               place   date 
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S.NO                      NAME AGE SEX ALCOHOL DRUG INT ASCITES PEDAL ED HEP ENCE UGI BLEED
1 KAMALAKANNAN 45 m yes no yes yes no no
2 GURUNATHAN 70 m no no yes no no no
3 SELVI 25 f no no yes yes no yes
4 DURAISAMY 44 m yes no no no no no
5 PITCHAI 52 m yes no yes yes yes yes
6 VEERARAGHAVAN 45 m yes no yes yes yes yes
7 SELVARAJ 62 m yes no yes no no no
8 VENDA 36 f no no no no no no
9 HARIDAS 68 m no no yes yes no no
10 JOSEPH 70 m yes no yes yes no yes
11 PALANIAPPAN 54 m yes no yes yes no no
12 KUMAR 52 m yes no yes yes no yes
13 RAJENDRAN 34 m yes no yes yes no yes
14 SAROJA 30 f yes no yes yes no no
15 MANIKANDAN 78 m yes no yes yes yes yes
16 SWAMINATHAN 57 m no no yes yes no no
17 GOPAL 45 m yes no no no no no
18 NARAYANAN 62 m yes no no no no no
19 ARAVINDAN 60 m yes no yes yes no yes
20 GOPAL 39 m no no yes yes no no
21 RAMESH 40 m no no yes yes no yes
22 SURYA NARAYANAN 43 m no no yes yes no no
23 DEENADAYALAN 56 m yes no yes yes no yes
24 SAMINATHAN 58 m yes no yes yes yes yes
25 MURUGAN 59 m yes no yes yes yes yes
26 MALLIGA 26 f no no yes no no no
27 GANESAN 66 m no no yes no no no
28 THAMBIDURAI 56 m yes no yes yes yes no
29 RAJAN 50 m no no yes yes no no
30 PENCILLIAH 58 m yes no yes yes no no
31 KARPAGAM 49 f yes no yes yes no yes
32 SELVI 48 f no no no no no no
T.B D.B SGOT SGPT ALP T.P ALBUMIN SUGAR UREA CREAT HB TC
3.4 2 84 98 120 6.6 3.2 98 32 1.1 9 4000
0.7 0.2 31 41 76 6.7 3.5 82 31 1.1 7 6400
1.2 0.3 70 87 145 6 2.6 123 40 1.3 8 4500
2.4 1 143 200 240 6.4 3.6 100 24 1 9.8 7600
12.6 5.6 124 223 256 6 2.9 60 40 1.5 7.3 11800
17.8 7.8 80 89 120 6 2.8 56 32 1.3 9.8 10000
0.7 0.2 45 43 112 6.8 3.5 76 21 1 10.2 3400
2.4 1 132 123 146 6.5 4.4 98 16 1.1 11 4000
3.4 1.4 72 78 132 6.2 3.8 122 26 1.2 10.5 5400
10.4 6.7 46 31 76 6 3.1 55 36 1.3 9.9 3200
2.1 1.2 43 40 67 6.6 2.9 56 22 1 9.8 10900
1.2 0.4 92 99 120 6 3.5 67 31 1.3 10.2 9700
0.8 0.1 149 99 56 5.4 4.3 81 29 0.8 11 2500
5.6 3.2 31 31 88 5.9 3.2 93 26 0.7 9.9 3200
11.8 3.5 77 67 99 6.7 2.7 67 40 1.2 7.8 6000
3.2 1.4 42 40 98 6.4 3.2 78 21 1 12 7600
3.6 2.2 200 189 231 6 3.3 98 34 0.9 11 6100
4.3 1.2 67 76 112 6.8 3.3 89 31 1 12 7890
4.5 2 44 45 99 6.3 3 45 27 1.3 9 3500
0.9 0.2 99 124 145 6.7 3.3 78 12 0.6 12 8900
4.7 1.8 34 31 110 6 2.8 78 22 1.1 9.8 2400
3.4 1.4 72 78 132 6.2 3.8 122 26 1.2 10.5 5400
11.2 8.9 56 67 91 6.9 3.5 87 30 1.1 9.2 3900
13.6 5.6 124 223 256 6 3 60 40 1.5 6.3 11800
10.8 5.6 124 223 256 6 3 60 40 1.5 5.3 11800
0.9 0.2 44 40 111 6.2 3.8 89 31 0.7 11.2 6100
1.9 0.7 56 45 120 6.6 3.6 67 21 0.9 12 7390
11 5.8 78 91 78 6 2.9 60 34 1.3 9 3100
10.9 4.7 45 46 100 6.4 3.1 84 28 0.9 10 4500
0.9 0.2 42 47 120 6.9 3.7 89 31 1.1 13 5600
11.2 6.7 46 45 76 6 3 99 30 1.2 9.9 7700
2.4 1 132 123 146 6.5 4.1 98 16 1.1 11 4000
PLT ESR INR POR DOP CXR XRAY LS|| USG UGIS
4 34 2.5 PHT N N CLD  GRADE 1 varices
1.52 62 1.2 PHT N N CLD GRADE 1 Varices
1.1 30 1.5 PHT N N CLD GRADE 3 Varices
3.5 20 1 NO N N CLD GASTRIC EROSIONS
1.2 46 2.8 PHT PLEU EFF N CLD GRADE 3 Varices
2.5 32 2.5 PHT PLEU EFF N CLD GRADE 3 Varices
0.9 12 1.5 PHT PLEU EFF N CLD N
3.5 10 1 NO N N CLD N
1.5 30 1.6 PHT N N CLD GRADE 1 Varices
1.4 42 2.1 PHT PLEU EFF OSTEOPOROTIC CLD GRADE 3 Varices
4.2 30 1.6 PHT N N CLD N
2.6 30 1.2 PHT N N CLD GRADE 3 Varices
1 30 1.5 PHT N N CLD GRADE 1 Varices
0.8 30 2 PHT N N CLD GASTRIC EROSIONS
1 23 3 PHT PLEU EFF OSTEOPOROTIC CLD GRADE 3 Varices
1.8 12 1.2 PHT N N CLD PROMINENT VEINS
2.3 20 1 PHT N N CLD N
3.3 11 1.2 PHT N N CLD N
3.7 22 2.1 PHT PLEU EFF OSTEOPOROTIC CLD GRADE 3 Varices
1.6 17 1.4 PHT N N CLD N
1.2 36 1.9 PHT N N CLD PROMINENT VEINS
3.9 30 1.6 PHT N N CLD GRADE 1 Varices
0.9 21 2 PHT N N CLD GRADE 2 VARICES
1.2 46 2.8 PHT PLEU EFF N CLD GRADE 3 Varices
1.2 46 2.8 PHT PLEU EFF N CLD GRADE 3 Varices
1.7 19 1 PHT N N CLD NORMAL
3.8 10 1 PHT N N CLD PROMINENT VEINS
0.9 29 2.6 PHT N N CLD GRADE 3 Varices
1.2 10 1.8 PHT N N CLD GRADE 1 Varices
1.9 14 1.6 PHT N N CLD GRADE 1 Varices
4.4 12 1.8 PHT PLEU EFF N CLD GRADE 2 VARICES
3.5 10 1 NO N N CLD N
HBsAG anti HCV CAL PO4 VIT D3 PTH BMD CHILD'S DIAGNOSIS ANA
neg neg 9.8 3 10.1 39.46 -2.8 C ALD NA
neg positive 9 4 22.79 39.46 -1.5 B HEP C CLD NA
neg positive 10 3 36.45 42 -0.8 B HEP C NA
neg neg 9.6 3.2 20.23 33.5 -0.6 A ALD NA
neg neg 9 4.5 8.9 70 -2.8 C ALD NA
neg neg 9.2 3.3 20 65 -1.3 C ALD NA
neg neg 9.1 3.6 33.5 42 -0.9 A ALD NA
neg positive 9.1 3.8 42 60.06 -0.9 A HEP C NEG
pos NEG 9 4 10.23 65 -3.3 B HEP B NA
neg neg 9.1 4.3 11 56 -3 C ALD NA
neg neg 8.9 2.3 33 43.22 -1 B ALD NA
neg neg 8 3.1 9.99 26 -0.6 B ALD NA
neg neg 7.9 4 42.9 59.12 -1.2 B ALD NA
neg neg 10 2 30.09 77 -1.6 C ALD NA
pos neg 8.9 3.5 3.3 80 -3.2 C HEP B ,ALD NA
neg positive 9.1 3.3 15.65 45.22 -0.1 A HEP C NA
neg neg 10.9 2.1 25.52 41.11 -0.6 A ALD NA
neg neg 11 3.3 20.08 40.32 -1 A ALD NA
neg neg 9.2 4.1 9 55.5 -2.5 C ALD NA
pos neg 9.8 2.5 10.21 33.33 -2.9 A HEP B NA
pos neg 9.8 3.5 14.97 42.19 -0.5 C HEP B NA
pos neg 9 4 10.23 65 -3.6 B HEP B NA
neg neg 9.1 3.4 8.6 45 -1.2 C ALD NA
neg neg 8.8 4.5 8.9 45 -2.8 C ALD NA
neg neg 9.2 4.5 8.9 46 -2.8 C ALD NA
pos neg 10.3 2.1 27.75 41 -0.2 A HEP B NA
pos neg 9.2 2.8 11 35.76 -1.5 A HEP B NA
neg neg 8.7 4.3 9.87 56.64 -2.9 C ALD NA
neg positive 8.7 3.8 13.89 61.1 -1.3 B HEP C NA 
neg neg 9.8 3.6 21.23 34.45 -0.9 A ALD NA
neg neg 9.3 4.3 10.08 56 -2.6 C ALD NA
neg positive 9.1 3.8 42 60.06 -0.9 A HEP C NA
ANTI LKM AMA SMA CERULOP LIVER BIO VITD STAT BMD
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND N OSTEOPENIA
NA NA NA NA ND N NORMAL
NA NA NA NA ND N NORMAL
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND N NORMAL
NA NA NA NA ND N NORMAL
NEG NEG NEG NA CIRRHOSIS N NORMAL
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND N OSTEOPENIA
NA NA NA NA ND LOW NORMAL
NA NA NA NA ND N OSTEOPENIA
NA NA NA NA ND N OSTEOPENIA
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND N NORMAL
NA NA NA NA ND N NORMAL
NA NA NA NA ND N OSTEOPENIA
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND N NORMAL
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND N NORMAL
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND N OSTEOPENIA
NA NA NA NA ND N NORMAL
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA CIRRHOSIS N NORMAL
33 DEVANATHAN 47 m no no yes yes no no
34 SIVAKUMAR 65 m no no yes yes no yes
35 SUBRAMANI 63 m no no no no no yes
36 PARVATHI 41 f yes no yes yes no no
37 MAHESWARI 47 f no no yes yes no no
38 CHENGAMMAL 43 f no no no no no yes
39 CHENNIAPPAN 61 m yes no yes yes no no
40 FRANCIS 47 m yes no no no no yes
41 MOHAMMED BASHA 43 m no no no no no yes
42 RAJAIAH 49 m no no yes yes no no
43 XAVIER 47 m yes no yes yes no no
44 JANANATHAN 54 m no no yes yes yes yes
45 GURUSAMY 53 m yes no yes yes yes yes
46 KUMAR 59 m yes no yes no no yes
47 KARTHIKEYAN 50 m yes no yes yes yes yes
48 BABU 60 m no no yes yes no no
49 THULASIAMMAL 33 f no no no no no no
50 SIVAKAMI 42 f no no yes yes no no
51 MANI 65 m no no yes yes no yes
52 LOGANATHAN 63 m no no no no no yes
53 CHELLAMMAL 41 f yes no yes yes no no
54 NAZEER BEGUM 47 f no no yes yes no no
55 MARIAMMAL 43 f no no no no no yes
3.4 1.4 72 78 132 6.2 3.8 122 23 1.2 10.5 5400
0.9 0.3 103 112 390 5.7 2.8 66 20 0.9 11 4200
4.8 2.1 43 32 142 6.9 3.7 98 32 0.8 10 3400
0.9 0.3 78 87 121 6.8 3.3 67 24 0.9 11 7200
3.2 1.6 120 132 99 6.2 2.9 86 18 1.1 12 1900
7.8 2.2 150 200 180 6.3 3.7 54 32 1.3 9.8 9800
5.9 3.2 76 67 99 6.7 3.6 140 11 1 6.7 1800
9.6 5.4 89 78 100 6 2.8 109 17 1.1 5 2500
3.6 2.2 200 189 231 6 3.3 56 32 1.3 9.8 10000
4.3 1.2 67 76 112 6.8 3.3 76 21 1 10.2 3400
4.5 2 44 45 99 6.3 3 98 16 1.1 11 4000
0.8 0.1 149 99 56 5.4 4.2 81 29 0.8 11 2500
12.2 5.6 124 223 256 6 2.9 60 40 1.5 7.3 11800
2.1 1 77 80 100 6.8 4 80 12 0.8 10.5 10000
11.6 3.5 77 67 99 6.7 3.6 67 40 1.2 7.8 6000
3.2 1.4 42 40 98 6.4 3.2 78 21 1 12 7600
3.6 2.2 200 189 231 6 3.3 98 34 0.9 11 6100
1.2 0.4 46 48 110 6.7 3.8 112 26 1.2 13 5600
0.9 0.3 103 112 390 5.7 2.8 66 20 0.9 11 4200
4.8 2.1 43 32 142 6.9 3.7 98 32 0.8 10 3400
0.9 0.3 78 87 121 6.8 3.3 67 24 0.9 11 7200
3.2 1.6 120 132 99 6.2 4.2 86 18 1.1 12 1900
7.8 2.2 150 200 180 6.3 3.7 54 32 1.3 9.8 9800
1.5 30 1.6 PHT N N CLD GRADE 1 Varices
1.23 12 1.4 PHT PLEU EFF N CLD GRADE 1 Varices
2.45 30 2 PHT N N CLD GRADE 2 VARICES
4 23 1 PHT N N CLD N
1.1 12 1.2 PHT N N CLD N
3.2 29 2 PHT N N CLD GASTRIC EROSIONS
0.6 26 2.2 PHT N N CLD GRADE 1 Varices
0.89 30 1.7 PHT N N CLD GRADE 2 VARICES
2.5 17 1.4 PHT N N CLD N
0.9 36 1.9 PHT N N CLD PROMINENT VEINS
3.5 30 1.6 PHT N N CLD GRADE 1 Varices
1 30 1.5 PHT N N CLD GRADE 1 Varices
1.2 46 2.8 PHT PLEU EFF N CLD GRADE 3 Varices
2.2 20 1.8 PHT N N CLD GASTRIC EROSIONS
1 23 3 PHT PLEU EFF OSTEOPOROTIC CLD GRADE 3 Varices
1.8 12 1.2 PHT N N CLD PROMINENT VEINS
2.3 20 1 PHT N N CLD N
3.2 28 1.4 PHT N N CLD N
1.23 12 1.4 PHT PLEU EFF N CLD GRADE 1 Varices
2.45 30 2 PHT N N CLD GRADE 2 VARICES
4 23 1 PHT N N CLD N
1.1 12 1.2 PHT N N CLD N
3.2 29 2 PHT N N CLD GASTRIC EROSIONS
pos neg 10 4 10.23 65 -1.6 B HEP B NA
pos neg 9.5 2.8 11 55 -1.6 B HEP B NA
neg positive 8.7 2.5 6.78 57 -1.5 B HEP C NA
neg neg 7.8 4 5.43 31 -1 B ALD NA
neg positive 9.2 3.8 19.81 24.42 -0.8 B HEP C NA
pos neg 9.9 4.2 7.8 26.78 -1.5 B HEP B NA
neg neg 9.2 4.1 9.92 63 -1 B ALD NA
neg neg 11 4.5 17.79 31.12 -0.9 C ALD NA
pos neg 9.8 2.5 10.21 33.33 -2.9 A HEP B NA
pos neg 9.8 3.5 14.97 42.19 -0.5 C HEP B NA
pos neg 9.1 4 10.23 65 -1.6 B HEP B NA
pos neg 8.9 4 42.9 59.12 -1.2 B HEP B NA
neg neg 8 4.5 8.9 70 -2.8 C ALD NA
neg neg 7.6 3.3 5.5 60 -2 B ALD NA
pos neg 8.1 3.5 3.3 80 -3.2 C HEP B ,ALD NA
neg positive 9.1 3.3 15.65 45.22 -0.1 A HEP C NA
neg neg 10.9 2.1 25.52 41.11 -0.6 A ALD NA
neg positive 11.2 5.6 12.21 36.9 -1.2 A HEP C NA
pos neg 9.5 2.8 11 55 -1.6 B HEP B NA
neg positive 8.7 2.5 6.78 57 -1.5 B HEP C NA
neg neg 9.4 4 5.43 31 -3.1 C ALD NA
neg positive 9.2 3.8 19.81 24.42 -0.8 B HEP C NA
pos neg 9.9 4.2 7.8 26.78 -1.5 B HEP B NA
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND N NORMAL
NA NA NA NA ND N NORMAL
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND N NORMAL
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND N NORMAL
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND N OSTEOPENIA
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND N NORMAL
NA NA NA NA ND N NORMAL
NA NA NA NA ND N NORMAL
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND LOW OSTEOPENIA
NA NA NA NA ND LOW OSTEOPOROSIS
NA NA NA NA ND N NORMAL
NA NA NA NA ND N NORMAL
